Costs and Outcomes of Heberprot-P® Treatment in Patients with Diabetic Foot Ulcer from Ramón López Peña Polyclinic

Authors

  • Naifi Hierrezuelo Rojas Policlínico Ramón López Peña
  • Paula Fernández González
  • Elizabeth Girón Pérez

Keywords:

economic assessment, diabetic foot ulcer, Heberprot-P®, diabetes mellitus

Abstract

Introduction: Diabetic foot ulcer is one of the main causes of morbidity and disability, with an important repercussion due to the economic burden of the disease and from the social point of view, due to the decrease in patients' quality of life.

Objective: To assess costs and outcomes of outpatient treatment with Heberpro-P® for the care of patients with diabetic foot ulcers.

Methods: A descriptive, longitudinal and retrospective study was carried out of 22 patients with diabetic foot treated with Heberprot-P®, in the consultation for such purposes of Ramón López Peña Polyclinic in 2019.

Results: 63.6% of the patients who came for consultation presented zero risk foot; neuroinfectious ulcer was the one with the highest incidence of presentation (94.5%). An effectiveness rate of 95.4% of the total of treated cases was obtained. Most of those treated needed three to eight bulbs of the medication, with an average of five treatment sessions per patient, at an average cost of 3549.8 Cuban pesos per treated case.

Conclusions: Treatment with Heberprot-P® is highly effective for the healing of diabetic foot ulcers, largely avoiding amputations of lower limbs of patients with diabetes mellitus, with a consequent decrease in the economic cost of these health interventions for the country.

 

Downloads

Download data is not yet available.

Downloads

Published

2022-03-14

How to Cite

1.
Hierrezuelo Rojas N, Fernández González P, Girón Pérez E. Costs and Outcomes of Heberprot-P® Treatment in Patients with Diabetic Foot Ulcer from Ramón López Peña Polyclinic. Rev cuba med gen integr [Internet]. 2022 Mar. 14 [cited 2025 Apr. 19];38(1). Available from: https://revmgi.sld.cu/index.php/mgi/article/view/1692

Issue

Vol. 38 No. 1 (2022): enero-marzo

Section

ARTÍCULOS ORIGINALES

License

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).